A temporary spike: Investigating Lennox-Gastaut syndrome incidence in the US following FDA approval of cannabidiol
{{output}}
Objective: In June 2018, the US Food and Drug Administration (FDA) approved pharmaceutical grade cannabidiol (CBD; Epidiolex®) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). We sought to examine whe... ...
